Aclidinium

What is Aclidinium?[edit | edit source]

Aclidinium (Tudorza pressair) is an anticholinergic used as a maintenance treatment for chronic obstructive pulmonary disease (COPD).

Aclidinium bromide

Aclidinium (Tudorza pressair) is a prescription medicine to treat chronic obstructive pulmonary disease (COPD). COPD is a long-term (chronic) lung disease that includes chronic bronchitis, emphysema, or both.
Aclidinium (Tudorza pressair) is an anticholinergic medicine. Anticholinergic medicines help the muscles around the airways in your lungs stay relaxed to prevent symptoms such as wheezing, cough, chest tightness, and shortness of breath.

Aclidinium bromide is a long-acting antimuscarinic agent, which is often referred to as an anticholinergic.
It has similar affinity to the subtypes of muscarinic receptors M1 to M5. In the airways, it exhibits pharmacological effects through inhibition of M3 receptor at the smooth muscle leading to bronchodilation.
The bronchodilation following inhalation of aclidinium bromide is predominantly a site-specific effect.

This medicine cannot be used in patients who:

have a severe allergy to milk proteins.
are allergic to aclidinium bromide or any of the ingredients in Tudorza pressair.

Avoid administrations of Tudorza pressair with other anticholinergic-containing drugs.

Recommended dosage:

The recommended dose of Tudorza pressair is one oral inhalation of 400 mcg, twice daily (morning and evening approximately 12 hours apart).

Administration:

Use Tudorza pressair exactly as prescribed. Do not use Tudorza pressair more often than prescribed or take more medicine than prescribed for you.
The usual dose of Tudorza pressair is 1 oral inhalation 2 times a day. Each dose should be about 12 hours apart.
If you miss a dose of Tudorza pressair, skip the missed dose. Take your next dose at your usual time. Do not take 2 doses at one time.
Do not use other medicines that contain an anticholinergic for any reason. Ask your doctor or pharmacist if any of your other medicines are anticholinergic medicines.
Tudorza pressair does not relieve sudden symptoms of COPD and you should not use extra doses of Tudorza pressair to relieve these sudden symptoms. Always have a rescue inhaler medicine with you to treat sudden symptoms. If you do not have a rescue inhaler medicine, call your doctor to have one prescribed for you.

This medicine is available in fallowing doasage form:

As Inhalation powder; The multi-dose device is a dry powder inhaler metering 400 mcg of aclidinium bromide per actuation.

This medicine is available in fallowing brand namesː

The most common side effects of this medicine include:

Tudorza pressair can cause serious side effects including:

Tudorza pressair is intended as a twice-daily maintenance treatment for COPD and is not indicated for the initial treatment of acute episodes of bronchospasm (i.e., rescue therapy).
Inhaled medicines, including Tudorza pressair, may cause paradoxical bronchospasm. If this occurs, treatment with Tudorza pressair should be stopped and other treatments considered.
Tudorza pressair should be used with caution in patients with narrow-angle glaucoma. Use with caution in patients with narrow-angle glaucoma and instruct patients to consult a physician immediately if this occurs.
Tudorza pressair should be used with caution in patients with urinary retention. Use with caution in patients with prostatic hyperplasia or bladder-neck obstruction and instruct patients to consult a physician immediately if this occurs.
Immediate hypersensitivity reactions, including anaphylaxis, angioedema (including swelling of the lips, tongue, or throat), urticaria, rash, bronchospasm, or itching, have occurred after administration of Tudorza pressair. Discontinue Tudorza pressair at once and consider alternatives if immediate hypersensitivity reactions, including angioedema, bronchospasm, or anaphylaxis occur.
Aclidinium has not been implicated in causing liver enzyme elevations or clinically apparent acute liver injury.

No case of overdose has been reported in clinical studies with Tudorza pressair.

There are no adequate and well controlled studies of Tudorza pressair in pregnant women to inform drug associated risks.

Tudorza pressair is approved for use in the maintenance treatment of bronchospasm associated with COPD.
COPD does not normally occur in children.
The safety and effectiveness of Tudorza pressair in pediatric patients have not been established.

AstraZeneca Pharmaceuticals LP, Wilmington, DE Under license of ALMIRALL, S.A.

Store Tudorza pressair at room temperature between 68°F to 77°F (20°C to 25°C) in the sealed bag that it comes in until you are ready to use Tudorza pressair. Do not open the sealed bag until you are ready to use a dose of Tudorza pressair.
Keep Tudorza pressair in a dry place.
Do not store the inhaler on a vibrating surface.

Aclidinium Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.